The Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Administrators, clinicians, data manager / clinical research professionals, fellows-in-training, investigators, laboratory technicians, MD/PhDs, nurses, nurse practitioners, pharmacists, physician assistants, and other allied health professional attendees benefit from a full scientific program that addresses the most timely issues in hematopoietic cell transplantation and cellular therapy.

View all videos

The 2022 Tandem Meetings

The Tandem Meetings I Transplantation & Cellular Therapy Meetings

23–26 April 2022 | Salt Lake City, UT

View all videos

; VJHemOnc @VJHemOnc ·

20 Dec 1737397492143010240

At #ASH23, @Eddie_Cliff (@BrighamWomens) shared insights from the POLARIX trial, revealing differences in the efficacy of R-CHP between subgroups of patients with #DLBCL.

Watch here:

👉

#Lymphoma #LYsm #TrialUpdate #CTSM #HemOnc @ASH_Hematology

POLARIX: R-CHP is more effective in the subgroup of DLBCL patients with activated B-cell origin

Edward Cliff, MPH, MBBS, Brigham and Women’s Hospital, Boston, MA, speaks on the POLARIX trial (NCT03274492), focusi...

ow.ly

Reply on Twitter 1737397492143010240 Retweet on Twitter 1737397492143010240 1 Like on Twitter 1737397492143010240 4 View Tweet 1737397492143010240

Retweet on Twitter VJHemOnc Retweeted

; Mohamad Mohty @Mohty_EBMT ·

19 Dec 1737133182682624359

Please spread the message and book your calendar
@COMyCongress @TheIACH

Reply on Twitter 1737133182682624359 Retweet on Twitter 1737133182682624359 12 Like on Twitter 1737133182682624359 42 View Tweet 1737133182682624359

; VJHemOnc @VJHemOnc ·

19 Dec 1737171070262620299

Want to hear about the highlights in the field of CLL from #ASH23, with a focus on the FLAIR study?

Then check out our interview with @DrMDavids of @DanaFarber here:

👉

#CLLsm #LeuSM #Leukemia #CTSM #HemOnc #ASH23 @ASH_hematology

CLL highlights from ASH 2023: the FLAIR study

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the highlights in the space of chronic lym...

ow.ly

Reply on Twitter 1737171070262620299 Retweet on Twitter 1737171070262620299 2 Like on Twitter 1737171070262620299 7 View Tweet 1737171070262620299

; VJHemOnc @VJHemOnc ·

19 Dec 1737042631354441836

🎥 @thomas_cluzeau of @CHUdeNice talks on the preliminary results of the VENTOGRAPH trial of AZA, VEN, and DLI in MDS and AML following AHSCT relapse.

Watch here:

👉

#MDSsm #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc #ASH23 @ASH_hematology

VENTOGRAPH trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following AHSCT

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the preliminary findings of the ...

ow.ly

Reply on Twitter 1737042631354441836 Retweet on Twitter 1737042631354441836 0 Like on Twitter 1737042631354441836 0 View Tweet 1737042631354441836

; VJHemOnc @VJHemOnc ·

18 Dec 1736801040341553657

Prof. John Gribben (@QMBCI) gave a wonderful insight into axi-cel in R/R #FollicularLymphoma at #ASH23 with an updated comparison of ZUMA-5 and SCHOLAR-5.

Watch here:

👉

#LYMsm #Lymphoma #NonHodgkinLymphoma #ImmunoOnc #HemOnc @ASH_hematology

Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, comments on the updated 4-year ...

ow.ly